Background {#Sec1}
==========

The validity and credibility of the results of a systematic review of diagnostic test accuracy studies depend not only on the methodological quality of the included studies but also on the absence of selective reporting \[[@CR1]-[@CR3]\]. Knowledge about the principles of selective reporting can help with the interpretation of the results of a meta-analysis.

A sample-size effect in randomized trials has been described before. Published trials with smaller sample sizes tend to have larger and more favourable effects compared to studies with larger sample sizes \[[@CR4],[@CR5]\]. This phenomenon may occur for several reasons. It has been suggested that smaller studies are more likely to be published when they show significant positive results. Larger studies may more likely be submitted, accepted and published regardless of their estimated effect. This mechanism, which is called small-study effect, can hamper the validity of a systematic review by overestimating the 'true' effect \[[@CR3],[@CR6]-[@CR8]\].

In addition to a small-study effect, meta-analyses of randomized trials may also be influenced by the problems arising from a time-lag effect. This effect can result from variability in the time it takes to complete and publish a study report, which may depend on the direction and strength of the trial results \[[@CR9]\]. Empirical studies have indicated that negative or null results take approximately two or three more years to be published compared to positive results \[[@CR3],[@CR10]\]. This time-lag effect could influence the meta-analysis and has implications for the timing of a review, the inclusion of on-going studies, and for updating the review.

Studying time-lag effects in diagnostic studies is not currently possible due to the lack of registration of such studies. However, overarching time trends, the tendency for study findings to change over time within a review, can be used as a proxy for time-lag effects. Although time-lag effects are only one reason for a change in results over time within a review, discovery of time trends would increase concern about the possible presence of time-lag effects in diagnostic accuracy studies.

Whereas these effects are well known and described for randomized trials, it is unclear whether they also translate to diagnostic accuracy studies \[[@CR11]-[@CR13]\]. Publication of diagnostic accuracy studies may be influenced by a different set of factors than randomized trials. In general, test accuracy studies tend to rely less on statistical significance testing than randomized trials. Many studies do not report confidence intervals around estimates \[[@CR14]\], and sample size calculations based on a minimally relevant performance levels are typically absent \[[@CR15]\]. However, there is some evidence of a failure to publish completed research projects. Korevaar *et al.* compared registry information for test accuracy studies to published reports and concluded that failure to publish and selective reporting are also present in test accuracy studies \[[@CR16]\]. However, the mechanisms driving these in test accuracy studies are not understood.

In this study we aimed to assess whether meta-analyses of diagnostic test accuracy suffer from small-study effects or time trends, using a set of recently published systematic reviews of such studies.

Methods {#Sec2}
=======

Selection of reviews and meta-analyses {#Sec3}
--------------------------------------

This study was part of a meta-epidemiological project on systematic reviews of diagnostic accuracy studies. On 12 September 2012, MEDLINE and EMBASE were searched for systematic reviews on test accuracy studies published between 1 May 2012 and 11 September 2012. For our analysis, we limited inclusion to reviews with a meta-analysis for which we were able to obtain all two-by-two classification tables of the studies included in the meta-analysis. A meta-analysis was defined as an analysis producing a summary estimate for at least one accuracy statistic or, alternatively, producing a summary ROC curve (sROC). Reviews of tests in animals, of prognostic tests, and of individual patient data were excluded, as there may be other effects related to publication in these types of studies. Only English language reviews were included. The full text of the search strategy is available in Additional file [1](#MOESM1){ref-type="media"}.

Data extraction {#Sec4}
---------------

Data were extracted using an online structured data-extraction form. An independent double data-extraction pilot was performed for a subset of the reviews (30%) until all authors agreed on the items of the data-extraction form. After that, data were extracted by one reviewer (CN, EO or WvE) and checked by a second reviewer (CN, EO or WvE) for discrepancies. Disagreements were resolved during a consensus meeting.

For each eligible review, we classified the type of test under evaluation and the total number of studies included in the meta-analyses. Data were then collected on the primary studies within one meta-analysis for each included review. Only one meta-analysis per review was included, so as not to give reviews with multiple meta-analysis extra weight and to avoid having to deal with correlated results. We selected the meta-analysis with the largest number of included primary studies, as the power to detect an association (if present) will be generally larger in meta-analyses with more primary studies. We assumed that there is no association between the number of studies in a meta-analysis and the associations of interest. For each primary study in a meta-analysis, we extracted the year of publication and data to populate the individual two-by-two accuracy table: the number of true positives, false negatives, false positives, and true negatives.

Whenever information on the primary studies was not available to us directly from the published review, we contacted the review authors. When we were unable to reach the author after sending two reminders or when authors could not provide the data, data were extracted from the original primary study reports. Failure to obtain this data from all studies in the meta-analysis was not a reason to exclude a meta-analysis. A second author checked the results of the data extraction.

Data analysis {#Sec5}
-------------

The aim of the analysis was to investigate the strength of the association between estimates of accuracy and sample size and between accuracy and time since first publication within a meta-analysis. These analyses were done in two steps. We first examined these associations within each included meta-analyses separately and then calculated a pooled estimate across all meta-analyses. This two-step approach was chosen to accommodate for differences in accuracy between meta-analyses related to differences in tests or fields.

These associations were examined for three commonly used measures of accuracy: sensitivity, specificity and the diagnostic odds ratio \[[@CR12],[@CR17],[@CR18]\]. To examine the association between sensitivity and sample size (that is the number of diseased subjects in a study), we performed a random effects meta-regression using logit sensitivity as the outcome and including the number of diseased subjects as a covariate in the model. To account for differences in the precision of sensitivity estimates between studies, we used the exact binomial distribution to model the within-study sampling error. This means that larger studies (that is studies with more diseased subjects) get more weight in the analysis. We used the exact binomial distribution (that is a non-linear mixed model) to avoid the need to add 0.5 to the data, which would have produced a downward bias in estimates which is more pronounced in smaller studies \[[@CR19],[@CR20]\]. The slopes and corresponding standard errors for sample size were estimated for each meta-analysis.

To prevent estimation problems when fitting this model, we excluded meta-analyses with four or fewer primary studies. In addition, primary studies without any diseased subject were also excluded from the analysis. To estimate the association across all meta-analyses, we then used the generic inverse variance method to get a pooled random effect estimate of this slope and its 95% confidence interval \[[@CR21]\]. The analysis for the association of specificity and sample size was done in the same way, only now using the number of non-diseased subjects as the measure of sample size.

To examine the association between the magnitude of the diagnostic odds ratio and total sample size, we first estimated the natural logarithm of the odds ratio in each individual study using Firth's correction method for small samples sizes \[[@CR22]\]. This correction method is preferred as it avoids the need of adding 0.5 in case the odds ratio estimate cannot be calculated. This method also reduces the bias that exists when estimating the odds ratio in small samples \[[@CR23]\]. We then fitted a meta-regression model for each meta-analysis separately using the log of the diagnostic odds ratio as the outcome and total sample size as the covariate. The inverse of the variances of the log odds ratios were used as weights (that is the generic inverse variance method was used) \[[@CR21]\]. Similar to the analysis of sensitivity and specificity, the slopes were estimated within each meta-analysis and then combined across the meta-analyses.

Similar analyses were done to look at associations between accuracy and time since first publication in a meta-analysis. Here the time interval between the date of publication of each study and the date of the oldest publication within a meta-analysis was used as the covariate in the regression model.

Both sample size and time since first publication were entered as continuous covariates to the model, assuming a linear association. To examine whether there were non-linear associations, we also classified studies in each meta-analysis into three groups using tertiles of sample size and tertiles of time since the first publication in years, respectively, and used these tertiles as categorical variables in the meta-regression.

The non-linear mixed effects models for (logit) sensitivity and specificity were performed in SAS using the NLMIXED procedure \[[@CR24]\]. All other analyses were conducted in the statistical package R \[[@CR25]\].

Subgroup analysis {#Sec6}
-----------------

In addition, separate analyses were carried out for imaging tests and for laboratory tests. Our rationale for this subgroup analysis was based on the observation that imaging studies generally have an implicit threshold. The reported accuracy in studies with an implicit threshold can be affected by the number of diseased patients and is more likely to change over time \[[@CR26]-[@CR28]\]. In addition, with imaging, gradual improvements in techniques may also induce time trends. We therefore hypothesized that a small study effect or time trends might act differently in imaging studies than in laboratory studies.

Results {#Sec7}
=======

Search results {#Sec8}
--------------

The search identified 1,273 references. After screening the titles and abstracts, 89 references were found potentially eligible and were read as full-text articles. Attempts were made to obtain the two-by-two tables of 53 eligible reviews. In three reviews, attempts were unsuccessful in extracting all of the two-by-two tables, resulting in 50 reviews (Additional file [2](#MOESM2){ref-type="media"}). In four reviews, the number of primary studies was four or lower and therefore excluded from the meta-epidemiological analyses. The remaining 46 meta-analyses contained a total of 859 primary studies (Additional file [3](#MOESM3){ref-type="media"} contains a list of the reviews).

Characteristics of the included reviews and meta-analyses {#Sec9}
---------------------------------------------------------

Fourteen reviews investigated a laboratory test, 27 an imaging test and 5 addressed clinical examinations. The selected meta-analyses had a median of 14 primary studies (interquartile range (IQR) 10--20). The median prevalence of the target condition in the studies was 47% (IQR: 24%-69%). More characteristics of the primary studies are presented in Table [1](#Tab1){ref-type="table"}.Table 1**Characteristics of primary studies (** ***N***  **= 859) across and within the included meta-analyses (** ***N***  **= 46)Number of sample sizeMedianInterquartile rangeMin-max**Across all meta-analysesNumber of diseased3317-630-1,358Number of non-diseased3618-1000-49,973Sample size8745-1853-50,008Time since first publication (years)63-100-42Median of the medianInterquartile range of mediansMin-max of the medianWithin meta-analysesNumber of diseased3118-415-154Number of non-diseased3818-870-11,276Sample size9446-33220-11,281Time since first publication (years)54-110-26

Sample size {#Sec10}
-----------

The median sample size of the included studies (*N* = 859) was 87 participants (IQR 45--185), ranging from extremely small (*N* = 3) to very large (*N* = 50,008). In total, there were 51,875 diseased participants and 525,838 non-diseased. This skewed distribution was mainly caused by a small set of studies on screening tests with very large samples but very few diseased compared to non-diseased.

The relative increase in DOR per 100 participants was 1.01 (95% CI 1.00 to 1.03; *P* = 0.07). This increase was mainly due to a relative increase in sensitivity of 1.11 per 100 additional diseased subjects (95% CI 0.98 to 1.26; *P* = 0.09). The analyses by tertiles confirmed that larger studies tend to produce higher estimates of accuracy, in particular for sensitivity (see Table [2](#Tab2){ref-type="table"}).Table 2**Small-study effects and time trendsAccuracy measure** ^**a**^**Relative increase** ^**b**^ **(95% CI)** ***P*** **valueT2 vs. T1** ^**c**^ **(95% CI)** ***P*** **valueT3 vs. T1** ^**c**^ **(95% CI)** ***P*** **value**Number of diseasedSensitivity1.11 (0.98 to 1.26) *P* = 0.091.08 (0.87 to 1.34) *P* = 0.501.22 (0.99 to 1.51) *P* = 0.06Number of non-diseasedSpecificity1.00 (0.99 to 1.02) *P* = 0.491.05 (0.83 to 1.33) *P* = 0.660.97 (0.73 to 1.28) *P* = 0.82Sample sizeDOR1.01 (1.00 to 1.03) *P* = 0.071.15 (0.94 to 1.40) *P* = 0.161.26 (0.96 to 1.64) *P* = 0.09Time since first publicationSensitivity0.89 (0.80 to 0.99) *P* = 0.040.61 (0.11 to 3.39) *P* = 0.570.59 (0.13 to 2.67) *P* = 0.49Time since first publicationSpecificity1.04 (0.90 to 1.19) *P* = 0.601.07 (0.85 to 1.35) *P* = 0.551.00 (0.76 to 1.32) *P* = 0.99Time since first publicationDOR0.94 (0.80 to 1.10) *P* = 0.420.94 (0.71 to 1.25) *P* = 0.680.93 (0.71 to 1.21) *P* = 0.57^a^The analyses were performed on the natural logarithm of the DOR and on the logit scale for sensitivity and specificity; ^b^relative increase for sensitivity, specificity, and DOR is reported per increase in 100 diseased, non-diseased, or total participants, respectively. For time since first publication, the relative increase is reported per 5 year increase; ^c^T1 is the lowest tertile of sample size or time since first publication, T3 the highest. DOR, diagnostic odds ratio.

Time of publication {#Sec11}
-------------------

The primary studies included in the meta-analyses were published between 1969 and 2012. Within meta-analyses, the median time interval between the first and the last included publication was 6 years (IQR: 3--10). For the DOR, there was a non-significant, negative association with time since first publication in a review, with a relative decrease in DOR of 0.94 per 5 years (95% CI 0.80 to 1.10; *P* = 0.42). Again this was mainly caused by the trend observed for sensitivity, with a relative decrease per 5 year of 0.89 (95% CI 0.80 to 0.99; *P* = 0.04. No association between time since first publication and specificity was observed. For detailed results see Table [2](#Tab2){ref-type="table"}.

Subgroup analysis {#Sec12}
-----------------

The subgroup analyses by type of test (that is imaging technique or laboratory test) revealed that the observed associations in the overall group were mainly caused by studies examining an imaging technique. In particular, a highly significant and positive association was found between sample size and sensitivity in imaging studies. In other words, larger imaging studies tend to report higher values of sensitivity than smaller studies examining the same technique. For detailed results see Table [3](#Tab3){ref-type="table"}.Table 3**Small-study effects and time trends assessed in subgroups of imaging and laboratory testsAccuracy measure** ^**a**^**Imaging test (** ***N***  **= 27 meta-analyses)Laboratory test (** ***N***  **= 14 meta-analyses)Relative increase** ^**b**^ **(95% CI)** ***P*** **valueRelative increase** ^**b**^ **(95% CI)** ***P*** **value**DiseasedSensitivity1.13 (1.05 to 1.22) *P* = 0.0021.01 (0.80 to 1.28) *P* = 0.92Non-diseasedSpecificity1.03 (0.86 to 1.24) *P* = 0.731.01 (1.00-1.02) *P* = 0.14Sample sizeDOR1.05 (0.97 to 1.14) *P* = 0.230.94 (0.63 to 1.40) *P* = 0.76Time since first publicationSensitivity0.88 (0.77 to 1.00) *P* = 0.050.94 (0.75 to 1.17) *P* = 0.57Time since first publicationSpecificity1.02 (0.87 to 1.19) *P* = 0.841.13 (0.80 to 1.58) *P* = 0.50Time since first publicationDOR\*0.89 (0.78 to 1.02) *P* = 0.090.87 (0.42 to 1.81) *P* = 0.71^a^The analyses were performed on the natural logarithm of the DOR and on the logit scale for sensitivity and specificity; ^b^relative increase for sensitivity, specificity, and DOR is reported per increase in 100 diseased, non-diseased, or total participants, respectively. For time since first publication, the relative increase is reported per 5 year increase. \*DOR, diagnostic odds ratio.

Discussion {#Sec13}
==========

We assessed the existence of small study effects and time trends in test accuracy meta-analyses using a meta-epidemiological analysis of a series of published systematic reviews. Opposite to what was expected, we observed no significant effects, and accuracy estimates of diagnostic studies tended to be lower in studies with a small sample size compared to studies with a larger sample size. Time trends were in the opposite direction; studies published after the first publications tended to report lower sensitivity. These trends were mainly caused by the subgroup of studies examining an imaging technique.

Our findings are in contrast with earlier findings for meta-analyses of randomized trials, where higher treatment effect sizes were reported to be strongly associated with small sample sizes \[[@CR7],[@CR8],[@CR29]\]. Nüesch *et al.* studied 13 meta-analyses with continuous outcomes and found on average a 0.21 (95% CI 0.08 to 0.34) higher effect size in small trials than in large trials \[[@CR7]\]. Dechartres *et al.* included 93 meta-analyses with binary outcomes. They concluded that the quartile of smallest trials had 32% (95% CI 18% to 43%) larger treatment effects than the quartile with the largest trials \[[@CR8]\]. The differences in effect size between small and large trials can be the result of the publication process, which selects positive and significant results over negative or null results \[[@CR30]\]. According to the review of Hopewell *et al.*, the odds of finding positive, significant results in a publication are four times higher than finding negative or null results \[[@CR31]\].

We consider it unlikely that the sample-size effect we have found for test accuracy meta-analyses results from an actual preference to publish small studies with low accuracy estimates, rather than small studies with higher accuracy estimates. Our findings on sample size effect are similar to those of Haines and colleagues. They found a similar relation between sample size and Youden's Index, a test statistic that captures test performance \[[@CR32]\]. In their evaluation, studies with larger samples had a higher Youden's Index. Haines *et al.* claimed that this relationship was attributable to prematurely stopping studies with poorer outcomes at smaller sample sizes while still publishing the results. It will be challenging to assess if this hypothesis is valid because power calculations are rarely reported in diagnostic accuracy studies \[[@CR33]\]. Another possibility is that the small-sample effect is a result of variability in methodological quality. In diagnostic research, some large studies could be based on routine care data. Such data may suffer from verification problems, resulting in higher accuracy \[[@CR34]\]. In any case, the mechanisms behind the small-study effects observed deserve further exploration.

Another issue that deserves attention when meta-analysing estimates of accuracy is when zero counts occur in the two-by-two table; in such cases, sensitivity or specificity estimates are 0% or 100%, or the odds ratio estimate is infinity. A standard solution is to add 0.5 to each cell of the two-by-two table \[[@CR35]\]. Although this correction prevents estimation problems, it does produce a downward bias in the estimates, which is more pronounced in small samples. To avoid imposing a positive association between the level of accuracy and sample size, it is critical to avoid the 0.5 correction. For this reason, we use non-linear mixed models to meta-analyse the logit transformed sensitivities or specificities within each review, with the exact binomial distribution to model the within-study sampling error \[[@CR19],[@CR20]\]. For our analyses with the odds ratio as the outcome, we estimate the log of the odds ratio in each individual study by using Firth's correction method \[[@CR22]\] to avoid the need of adding 0.5 \[[@CR23]\].

Our primary analysis was based on the assumption of a linear relationship between test accuracy and sample size or time since first publication. We assumed that if an association between sample size or time since first publication is present, a more or less linear association is most likely. As the actual relation might deviate, we also performed an additional analysis by tertiles of sample size or time since first publication as a way to examine potential non-linear associations. These analyses revealed no indications of strong non-linear associations.

The time trend observed in our DTA meta-analyses was limited, compared to several time trends identified for randomized trials \[[@CR3],[@CR9],[@CR35]\]. We observed a negative association between sensitivity and time after the first publication within a review. This direction is similar to the trend of randomized trials, with lower DORs in later studies. Similar to our results, the study of Sonnad *et al.* found that earlier published studies had higher accuracy, but the relation was not significant \[[@CR36]\].

A possible explanation for such a trend is that the design of studies may change over time, from explorative case control type studies to prospective studies in consecutive patients \[[@CR37]\]. In addition, the setting and targeted patients may change over time, with better understanding of the most useful application of a diagnostic test \[[@CR38]\]. It would be worthwhile to study if specific study characteristics, such as study setting or patient spectrum, change over time in a large cohort of primary diagnostic accuracy studies. In future studies it would also be worthwhile to investigate the separate the effects of sample size and time trends by jointly modelling them.

The trends in our meta-epidemiological study were more pronounced for the sensitivity of imaging tests. The reasons for this remain speculative. Differences in the inclusion or exclusion criteria or setting of a diagnostic study are more likely to affect the case-mix of patients with the target condition and therefore have a greater effect on sensitivity. High-resolution imaging techniques are often used at the end of a diagnostic pathway and determine further clinical actions. Convincing evidence showing high accuracy in a large number of patients may therefore be pursued.

The meticulous follow-up of a cohort of diagnostic accuracy studies would be a way of documenting the actual mechanisms in designing, reporting and publishing such studies, and would allow us to analyse to what extent non-random publication bias exists \[[@CR9],[@CR39]\]. Factors that influence the decision to submit or to accept a research article can also be studied from trial registers. In 2006, the International Committee of Journal Editors (ICMJE) established prospective registration of trials, defined as 'any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome' \[[@CR40]\]. At present, this definition does not seem to capture all test accuracy studies, and recent analyses have shown that only a small subset of such studies is currently registered before enrolment of the first patient \[[@CR41]\].

Conclusions {#Sec14}
===========

Awaiting further evidence, our study results lead us to conclude that some of the typical mechanisms associated with publication bias, which are well documented in the literature for randomized clinical trials, are less prominent in test accuracy research. Small-study effects seem to be reversed in meta-analyses on imaging tests, where larger studies tend to report higher sensitivity. Confirmation of the findings of our study may provide reassurance to those relying on the published literature for evidence of the performance of medical tests.

Additional files {#Sec15}
================

Additional file 1:**Full text of search strategy.** Full text search strategy used in this study to find reviews of diagnostic tests.Additional file 2:**Inclusion flow chart.** Flow chart showing how reviews were included in this study.Additional file 3:**List of included reviews.** References of reviews included in this study.
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